http://www.webbreakingnews.com/2016/09/03/independent-portfolio-consultants-inc-has-1340000-stake-in-merck-co-mrk/
http://www.thejournal.ie/epipen-mylan-explainer-2-2959963-Sep2016/
http://www.mondaq.com/australia/x/523738/Patent/Experimental%2Bevidence%2Bin%2Bpatent%2Bcases%2BDiscovery%2Bnot%2Bavailable%2Bfor%2Bexperiments%2Bon%2Bmatters%2Bno%2Blonger%2Bin%2Bissue
https://www.thestreet.com/story/13693062/1/will-merck-mrk-stock-be-hurt-by-discontinuing-osteoporosis-drug-development.html
http://www.dailymail.co.uk/~/article-3770804/index.html
http://www.finanznachrichten.de/nachrichten-2016-09/38476037-merck-discontinues-its-odanacatib-development-program-020.htm

http://www.dailymail.co.uk/~/article-3770745/index.html
http://www.4-traders.com//MERCK-CO-INC-13611/news/Merck-Provides-Update-on-Odanacatib-Development-Program-22996139/
http://www.pmlive.com/pharma_news/roches_checkpoint_inhibitor_tecentriq_aces_lung_cancer_trial_1119404
http://www.benzinga.com/general/biotech/16/09/8420417/merck-remains-stable-following-discontinuation-of-odanacatib-developme
https://www.thestreet.com/video/13693324/merck-to-discontinue-osteoporosis-drug-development.html
http://www.capital.fr/bourse/actualites/merck-co-abandonne-le-developpement-d-un-medicament-contre-l-osteoporose-1161059
http://www.fool.com/investing/2016/09/03/is-biogen-a-worthwhile-buyout-candidate.aspx?source=eptfxblnk0000004&utm_campaign=article&utm_medium=feed&utm_source=foxbusiness
http://www.wgmd.com/is-biogen-a-worthwhile-buyout-candidate/
http://www.emailwire.com/release/268748-China-Pediatric-Healthcare-Industry-Market-Trend-2016-Demand-Analysis-Growth-Research-201617.html
http://www.northjersey.com/cm/2.1593/news/business/merck-halts-development-of-osteoporosis-drug-due-to-stroke-risk-1.1653999
http://www.vancouversun.com/news/canada/isabel+wallace+make+sure+ebola+vaccine+canada+last+vaccine/12167502/story.html
http://www.proactiveinvestors.com/companies/news/147662/merck-axes-osteoporosis-treatment-odanacatib-147662.html
http://www.4-traders.com//POLR-CPTL-GLBL-HLTHCRE-GR-6306620/news/Polr-Cptl-Glbl-Hlthcre-Grth-Top-Ten-Equity-Holdings-and-Exposures-22997120/
http://www.zonebourse.com//actualite-bourse/MERCK-CO-abandonne-le-developpement-d-un-medicament-contre-l-osteoporose--22996861/
http://www.chemicalprocessing.com/articles/2016/light-replaces-ligands-for-synthesis/
http://www.mmm-online.com/media-news/mmms-top-5-stories-in-august-2016/article/519861/
http://www.humanosphere.org/global-health/2016/09/uganda-scores-major-victory-against-river-blindness-nears-eradication/
http://www.ssuchronicle.com/2016/09/02/cbcf-annual-health-and-wellness-luncheon-an-ounce-of-prevention-beats-a-pound-of-cure/
http://www.medpagetoday.com/InfectiousDisease/ZikaVirus/60009
http://www.finanznachrichten.de/nachrichten-2016-09/38477287-research-and-markets-foot-care-products-global-strategic-business-report-2022-leading-players-are-bazuka-compeed-daktarin-lamisil-at-scholl-008.htm


http://www.marketwatch.com/story/gelesis-appoints-new-chief-operating-officer-2016-09-02-215906

http://www.mmm-online.com/roundup/five-things-for-pharma-marketers-to-know-friday-september-2-2016/article/520374/
